The cardiovascular actions of DOPA mediated by the gene product of ocular albinism 1

Journal of Pharmacological Sciences

Volumn 126, Issue 1, 2014, Pages 14-20

  Goshima, Yoshio ^a   Nakamura, Fumio ^a   Masukawa, Daiki ^a   Chen, Sandy ^a   Koga, Motokazu ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Baroreceptor reflex; DOPA; GPCR; Neurotransmitter; Nucleus tractus solitarii

Indexed keywords

ADENYLATE CYCLASE; DOPAMINE 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; LEVODOPA; OCULAR ALBINISM 1; PHOSPHOLIPASE C; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPA; DRUG RECEPTOR; EYE PROTEIN; GPR143 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN BINDING;

BINDING AFFINITY; BRAIN STEM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVATION; FAINTNESS; GENE PRODUCT; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; NEGATIVE FEEDBACK; NONHUMAN; OCULAR ALBINISM 1 GENE; PARKINSON DISEASE; PRESSORECEPTOR REFLEX; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOLITARY TRACT NUCLEUS; ANIMAL; CHEMICALLY INDUCED; METABOLISM; PHYSIOLOGY; RAT;

ANIMALS; BAROREFLEX; DIHYDROXYPHENYLALANINE; EYE PROTEINS; HUMANS; HYPOTENSION; MEMBRANE GLYCOPROTEINS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; PROTEIN BINDING; RATS; RECEPTORS, DRUG; RECEPTORS, G-PROTEIN-COUPLED; SOLITARY NUCLEUS; SYNCOPE;

EID: 84909944309     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14R03CR     Document Type: Review

References (44)

1. Bartholini G, Burkard WP, Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature. 1967;215:852-853.
2. Ng KY, Chase TN, Colburn RW, Kopin IJ. L-Dopa-induced release of cerebral monoamines. Science. 1970;170:76-77.
3. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 1975;195:453-464.
4. Misu Y, Goshima Y, Ueda H, Okamura H. Neurobiology of L-DOPAergic systems. Prog Neurobiol. 1996;49:415-454.
5. Misu Y, Goshima Y. Is L-dopa an endogenous neurotransmitter? Trends Pharmacol Sci. 1993;14:119-123.
6. Nakamura S, Goshima Y, Yue JL, Miyamae T, Misu Y. Transmitter-like 3,4-dihydroxyphenylalanine is tonically released by nicotine in striata of conscious rats. Eur J Pharmacol. 1992;222:75-80.
7. Yue JL, Okamura H, Goshima Y, Nakamura S, Geffard M, Misu Y. Baroreceptor-aortic nerve-mediated release of endogenous L-3,4-dihydroxyphenylalanine and its tonic depressor function in the nucleus tractus solitarii of rats. Neuroscience. 1994;62:145-161.
8. Komori K, Uesaka S, Yamaoka H, Fujita K, Yamaoka K, Naitoh H, et al. Identification of L-dopa immunoreactivity in some neurons in the human mesencephalic region: a novel dopa neuron group? Neurosci Lett. 1993;157:13-16.
9. Okamura H, Kitahama K, Mons N, Ibata Y, Jouvet M, Geggard M. L-dopa-immunoreactive neurons in the rat hypothalamic tuberal region. Neurosci Lett. 1988;95:42-46.
10. Sugaya Y, Sasaki Y, Goshima Y, Kitahama K, Kusakabe T, Miyamae T, Kato T, Misu Y. Autoradiographic studies using L-[(14)C]DOPA and L-DOPA reveal regional Na(+)-dependent uptake of the neurotransmitter candidate L-DOPA in the CNS. Neuroscience. 2001;104:1-14.
11. Goshima Y, Kubo T, Misu Y. Biphasic actions of L-DOPA on the release of endogenous noradrenaline and dopamine from rat hypothalamic slices. Br J Pharmacol. 1986;89:229-234.
12. Kubo T, Yue JL, Goshima Y, Nakamura S, Misu Y. Evidence for L-dopa systems responsible for cardiovascular control in the nucleus tractus solitarii of the rat. Neurosci lett. 1992;140:153-156.
13. Akbar M, Ishihara K, Sasa M, Misu Y. Inhibition by L-3,4-dihydroxyphenylalanine of hippocampal CA1 neurons with facilitation of noradrenaline and gamma-aminobutyric acid release. Eur J Pharmacol. 2001;414:197-203.
14. Furukawa N, Goshima Y, Miyamae T, Sugiyama Y, Shimizu M, Ohshima E, et al. L-DOPA cyclohexyl ester is a novel potent and relatively stable competitive antagonist against L-DOPA among several L-DOPA ester compounds. Jpn J Pharmacol. 2000;82:40-47.
15. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al; Cgtp Collaborators. The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol. 2013;170:1459-1581.
16. Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS. L-DOPA is an endogenous ligand for OA1. PLoS Biology. 2008;6:e236.
17. Schiaffino MV, d'Addio M, Alloni A, Baschirotto C, Valetti C, Cortese K, et al. Ocular albinism: evidence for a defect in an intracellular signal transduction system. Nat Genet. 1999;23:108-112.
18. Garner A, Jay BS. Macromelanosomes in X-linked ocular albinism. Histopathology. 1980;4:243-254.
19. O'Donnell FE, Hambrick GW Jr, Green WR Jr, Iliff WJ, Stone DL. X-linked ocular albinism. An oculocutaneous macromelanosomal disorder. Arch Ophthalmol. 1976;94:1883-1892.
20. Jaeger CB, Ruggiero DA, Albert VR, Park DH, Joh TH, Reis DJ. Aromatic L-amino acid decarboxylase in the rat brain: immunocytochemical localization in neurons of the brain stem. Neuroscience. 1984;11:691-713.
21. Hiroshima Y, Miyamoto H, Nakamura F, Masukawa D, Yamamoto T, Muraoka H, et al. Ocular albinism 1 (OA1), a G-protein coupled receptor GPR143, is a receptor that mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii. Br J Pharmacol. 2014;171:403-414.
22. Goldstein M, Fuxe K, Hokfelt T. Characterization and tissue localization of catecholamine synthesizing enzymes. Pharmacol Rev. 1972;24:293-309.
23. Bugiardini R, Morgagni G, Pozzati A, Ottani F, Borghi A, Lenzi S, et al. Effect of oral levodopa and carbidopa on coronary spasm in variant angina pectoris. Am J Cardiol. 1987;60:489-493.
24. Judy WV, Watanabe AM, Henry DP, Besch HR Jr, Aprison B. Effect of l-dopa on sympathetic nerve activity and blood pressure in the spontaneously hypertensive rat. Circ Res. 1978;43:24-28.
25. Whitsett TL, Halushka PV, Goldberg LI. Attenuation of post-ganglionic sympathetic nerve activity by L-dopa. Circ Res. 1970;27:561-570.
26. Kohli JD. Peripheral dopamine receptors. Am J Hypertens. 1990;3:25S-28S.
27. Felder RA, Felder CC, Eisner GM, Jose PA. The dopamine receptor in adult and maturing kidney. Am J Physiol. 1989;257:F315-F327.
28. Dubocovich ML, Langer SZ. Dopamine and alpha adrenoceptor agonists inhibit neurotransmission in the cat spleen through different presynaptic receptors. J Pharmacol Exp Ther. 1980;212:144-152.
29. Blair ML, Reid IA, Ganong WF. Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs. J Pharmacol Exp Ther. 1977;202:209-215.
30. Krnjevic K, Phillis JW. Actions of certain amines on cerebral cortical neurones. Brit J Pharmacol. 1963;20:471-490.
31. Biscoe TJ, Evans RH, Headley PM, Martin MR, Watkins JC. Structure-activity relations of excitatory amino acids on frog and rat spinal neurones. Br J Pharmacol. 1976;58:373-382.
32. Miyamae T, Goshima Y, Shimizu M, Shibata T, Kawashima K, Ohshima E, et al. Some interactions of L-DOPA and its related compounds with glutamate receptors. Life Sci. 1999;64:1045-1054.
33. Talman WT, Perrone MH, Reis DJ. Evidence for L-glutamate as the neurotransmitter of baroreceptor afferent nerve fibers. Science. 1980;209:813-815.
34. Gordon FJ, Leone C. Non-NMDA receptors in the nucleus of the tractus solitarius play the predominant role in mediating aortic baroreceptor reflexes. Brain Res. 1991;568:319-322.
35. Yue JL, Goshima Y, Miyamae T, Misu Y. Evidence for L-dopa relevant to modulation of sympathetic activity in the rostral ventrolateral medulla of rats. Brain Res. 1993;629:310-314.
36. Yue JL, Goshima Y, Misu Y. Transmitter-like L-3,4-dihydroxyphenylalanine tonically functions to mediate vasodepressor control in the caudal ventrolateral medulla of rats. Neurosci Lett. 1993;159:103-106.
37. Urbanski RW, Sapru HN. Evidence for a sympathoexcitatory pathway from the nucleus tractus solitarii to the ventrolateral medullary pressor area. J Auton Nerv Syst. 1988;23:161-174.
38. Misu Y, Goshima Y, Miyamae T. Is DOPA a neurotransmitter? Trends Pharmacol Sci. 2002;23:262-268.
39. Masukawa D, Nakamura F, Koga M, Kamiya M, Chen S, Yamashita N, et al. Localization of ocular albinism-1 gene product GPR143 in the rat central nervous system. Neurosci Res. In press.
40. Goshima Y, Nakamura S, Misu Y. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther. 1991;258:466-471.
41. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829.
42. Goshima Y, Misu Y, Arai N, Misugi K. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease. Jpn J Pharmacol. 1991;55:93-100.
43. Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature. 1998;396:683-687.
44. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, et al. Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature. 1998;396:679-682.